ClinicalTrials.gg

Program

ruvonoflast

Its studies are mostly in Obesity · Cardiovascular Diseases, led by Rezera (formerly NodThera Limited).

Furthest: phase 2, since May 30, 20253 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Rezera (formerly NodThera Limited)30 open or runningphase 2since May 30, 2025Oct 30, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 30, 2023First study: phase 1 study in Cardiovascular DiseasesFirst studyNCT06129409 · 67 enrolled · United States
  2. May 30, 2025Phase 2 study in ObesityNCT07055516 · 176 enrolled · United States
  3. Oct 17, 2025Phase 2 study in ObesityNCT07220629 · 82 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07220629Obesity · United States2CompletedAug 21, 202682
NCT07055516Obesity · United States2CompletedMay 27, 2026176
NCT06129409Cardiovascular Diseases · United States1CompletedApr 15, 202467

How it is read

Names in the registry

  • “NT-0796”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.